Codiak Biosciences
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Douglas Williams
Employees
102
Country
United States
ISIN
US1920101060
WKN
000A2PJN7
Listings
0 Comments
Share your thoughts
FAQ
What is Codiak Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Codiak Biosciences stocks are traded under the ticker 32W.STU.
How many employees does Codiak Biosciences have?▼
As of September 04, 2026, the company has 102 employees.
In which sector is Codiak Biosciences located?▼
Codiak Biosciences operates in the Manufacturing sector.
When did Codiak Biosciences complete a stock split?▼
Codiak Biosciences has not had any recent stock splits.
Where is Codiak Biosciences headquartered?▼
Codiak Biosciences is headquartered in Cambridge, United States.